GSK has voluntarily recalled one lot of Ventolin Diskus 200 μg salbutamol (albuterol) DPIs in Canada due to "a manufacturing issue that may result in a small number of Ventolin Diskus devices not delivering the full number of doses in the device," the company said. The lot recalled is number 786G. According to GSK, the root cause of the manufacturing issue has … [Read more...] about GSK recalls lot of Ventolin Diskus in Canada
Business
Opiant Pharmaceuticals developing intranasal nalmefene for the treatment of opioid overdose
Opiant Pharmaceuticals has announced that, based on feedback from the FDA and positive data from a Phase I clinical study, the company plans to pursue a 505(b)(2) development path for its OPNT003 intranasal nalmefene for the treatment of opioid overdose. OPNT003 is formulated using Aegis Therapeutics' Intravail absorption enhancer, which Opiant licensed in 2017. … [Read more...] about Opiant Pharmaceuticals developing intranasal nalmefene for the treatment of opioid overdose
Teva launches QVAR RediHaler in the US
Teva Pharmaceutical Industries has announced the US launch of its QVAR RediHaler beclomethasone dipropionate HFA MDI, which was approved by the FDA in August 2017 for the treatment of asthma in patients aged 4 years and older. The RediHaler is a breath actuated device and requires no shaking or priming. The company is discontinuing sales of the previous version of … [Read more...] about Teva launches QVAR RediHaler in the US
OraPharma to co-promote Sprix nasal spray in the US
Egalet Corporation has terminated a co-promotion agreement with Septodont, the company said, and is now partnered with Valeant's OraPharma division for co-promotion of Sprix ketorolac tromethamine nasal spray to US dentists and oral surgeons. Sprix has been approved by the FDA since 2010 for short-term treatment of moderate-to-severe pain. Under the terms of the … [Read more...] about OraPharma to co-promote Sprix nasal spray in the US
Huons reportedly licenses budesonide/salmeterol DPI from Laboratoires SMB
According to Korea Biomedical Review, Korean pharmaceutical company Huons has licensed Zephirus busesonide/salmeterol, a dry powder formulation delivered using the Axahaler capsule-based inhaler, from Belgian pharmaceutical company Laboratoires SMB. Korea Biomedical Review reported that Huons CEO Um Key-an commented, “Respiratory disease is a disease that greatly … [Read more...] about Huons reportedly licenses budesonide/salmeterol DPI from Laboratoires SMB
Iconovo signs development and licensing agreement with Intas Pharmaceuticals for DPI
Iconovo AB announced that it has signed an agreement with Intas Pharmaceuticals for development and licensing of a DPI for the treatment of asthma and COPD, including the dry powder formulation and a device based on Iconovo's ICOres reservoir inhaler. According to Iconovo, the deal is worth €2.8 million and includes royalties. In June 2017, Iconovo announced the … [Read more...] about Iconovo signs development and licensing agreement with Intas Pharmaceuticals for DPI
Aerogen and Lyomark Pharma partner on nasally-inhaled surfactant for RDS
Aerogen Pharma and Lyomark Pharma have announced a partnership for development and commercialization of AP-002, a nasally-inhaled surfactant based on Lyomark's Alveofact bovine lung surfactant for the treatment of respiratory distress syndrome (RDS) in pre-term infants. According to Aerogen, the company has also initiated a Phase 2 study of AP-002 in Australia, with … [Read more...] about Aerogen and Lyomark Pharma partner on nasally-inhaled surfactant for RDS
Airware Labs agrees to acquire cannabis company for development of intranasal THC
Airware Labs Corporation has entered into a non-binding letter of intent to acquire a cannabis consulting company and grower doing business as Item 9 Labs with the goal of developing an intranasal THC product, Airware Labs Corp said. The agreement would be terminated if the two companies are unable to finalize terms by the end of the year. All of the products … [Read more...] about Airware Labs agrees to acquire cannabis company for development of intranasal THC
Savara gets $5 million from CFFT for AeroVanc development
Savara has received a development award of up to $5 million from Cystic Fibrosis Foundation Therapeutics (CFFT), which will support the Phase 3 AVAIL study of the AeroVanc DPI for the treatment of MRSA lung infections in cystic fibrosis patients, the company said. In 2013, CFFT awarded the company $1.7 million for Phase 2 development of AeroVanc. Savara announced … [Read more...] about Savara gets $5 million from CFFT for AeroVanc development
Chiesi and Kamada end agreement for European distribution of inhaled AAT
Kamada has announced that an agreement with Chiesi for European distribution of Kamada's inhaled Alpha-1 Antitrypsin (AAT) has been terminated. According to Kamada, the companies mutually agreed to end the agreement because Kamada recently withdrew its MAA for inhaled AAT, and "a European distribution agreement within the pact’s defined timeframe is not currently … [Read more...] about Chiesi and Kamada end agreement for European distribution of inhaled AAT